New drug duo challenges standard treatment in breast cancer trial
NCT ID NCT07294534
Summary
This study is testing whether two new experimental drugs (HLX87 and HLX22) work better than the current standard treatment when given before surgery for HER2-positive breast cancer. Researchers will enroll 817 adults with early-stage or locally advanced HER2-positive breast cancer who haven't had previous cancer treatments. The goal is to see if the new combination helps eliminate more cancer from the breast and lymph nodes before surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 + BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.